HONG KONG, Aug. 14, 2026 /PRNewswire/ — Restore, an innovative mini storage provider distinguished by clean, minimalist interiors, today announces 4 new store additions to its Hong Kong footprint. These include a brand-new store in Tsuen Wan, as well as capacity expansion to its existing facilities in Fo Tan, Kwai Chung, and Wong Chuk Hang. Pairing advanced smart storage features with a customer-first service philosophy, Restore is well known to leverage human-centric technology to deliver seamless, secure, and exceptionally convenient storage solutions.

First Tsuen Wan Store: A Different Mini Storage Experience Combining Clean Designs and Smart Tech

With its recent expansion to Tsuen Wan, Restore has grown its network to over 40 stores across the city, broadening its service reach to New Territories West to better serve local residents and businesses. To celebrate the opening of the new branch, the Tsuen Wan mini-storage is offering a grand opening promotion with average monthly fees from as low as HK$239 per month, available on a first-come, first-served basis.

In addition to expanding into new areas, Restore has concurrently expanded its existing branches in Fo Tan, Kwai Chung, and Wong Chuk Hang. By increasing its capacity in these three districts, Restore aims to offer a more diverse range of storage options to more effectively meet local customer needs, alongside its hallmark “0 prepayment, no lock-in” payment plans.

Smart tech for better customer convenience and protection

Restore stands out as one of the very few mini-storage companies adopting smart tech throughout all aspects of customer experience. Moving away from cumbersome move-in procedures of traditional storage facilities, Restore integrates human-centric technology into all facets of its facility design to significantly enhance both security and convenience for its users: 

• Smart locks combined with mechanical ones for dual protection: Customers enjoy 24/7 card-free facility access via smartphones. Each storage unit also pairs an independent electronic lock with a mechanical locking latch, delivering a dual-layered security system that perfectly balances modern convenience with robust protection.
• IoT systems for intelligent interior climate control:Restore’s facilities feature innovative IoT systems that track interior climate conditions. By replacing traditional manual inspections with data-driven management, Restore is able to effectively eliminate blind spots and response delays. This enables consistent facility climate control and therefore better peace of mind for customers.
• Paperless online account management: Customers are now able to book storage units, sign contracts, and manage their accounts online at their convenience. This paperless process eliminates the need to visit a branch in person, saving both time and effort.

Clear focus on specialized facilities dedicated to storage

Restore offers arguably the widest range of locker sizes and specialized storage options in the market. These include wardrobe units, book-shelf units, and double-decker lockers. It also offers comprehensive moving services enabling seamless customer move-ins.

To prioritize customer privacy and security, Restore’s facilities are designed exclusively for storage purposes. By keeping its spaces dedicated solely to storage, Restore minimizes foot traffic and maintains a quiet and safe environment where customers can comfortably access and organize their belongings.

New store locations

Tsuen Wan Storage: 13/F (Reception), Bonsun Industrial Building, 364-366 Sha Tsui Road, Tsuen Wan, NT

Fo Tan Storage: Units 703 (Reception), 704, 401 and 402, Hopeful Factory Center, 10-16 Wo Shing Street, Fo Tan

Kwai Chung Storage: 6/F (Reception) & 4/F & 5/F And 8/F, Kinwah Factory Building, 136-138 Tai Lin Pai Road, Kwai Chung, Hong Kong

Wong Chuk Hang Storage:
1. Unit C,D, 2/F (Reception) & And Unit C, 8/F, Sing Teck Factory Building, 44 Wong Chuk Hang Road, Hong Kong
2. Unit B, 9/F (Reception) & Unit A, 1/F And Unit B, 8/F, Shui Ki Industrial Building, 18 Wong Chuk Hang Road, Hong Kong

For more information contact:
66338008
hello@restore.space 

Wongs Jewellers won two categories at the 2026 UK Jewellery Awards and was shortlisted for Store Design of the Year for its Manchester showroom, a project supported by DG Display Showcase.

GUANGZHOU, China, Aug. 17, 2026 /PRNewswire/ — DG Display Showcase, a customized display and retail-space solution provider with more than 27 years of industry experience, is highlighting its work with UK independent jeweller Wongs Jewellers following the retailer’s recognition at the 2026 UK Jewellery Awards, held in London on July 8. Wongs Jewellers won Bridal Jewellery Retailer of the Year and Jewellery Retailer of the Year (five stores or fewer), while its Manchester store was shortlisted for Store Design of the Year and its “Welded by Wongs” initiative was shortlisted for Marketing/Social Media Campaign or Collaboration of the Year (Retail).

The UK Jewellery Awards, presented by Retail Jeweller and now in their 34th year, are among the UK jewellery industry’s longest-running and most established honours. Wongs Jewellers was shortlisted in four categories overall and ultimately won two awards on the night. Notably, the Manchester store had been open for less than a year at the time of its Store Design of the Year shortlisting, having launched in late 2025 as Wongs’ first location in the city.

For DG Display Showcase, the recognition provides a project context for its work as an international retail-space partner. DG Display Showcase supported Wongs Jewellers’ Manchester store through a one-stop process covering brand understanding, spatial planning, custom showcase production, material coordination, lighting coordination, transportation and after-sales maintenance and repair. The project was developed to connect the retailer’s heritage with a contemporary customer environment rather than treating display fixtures as standalone furniture.

Translating Jewellery Heritage Into Retail Space

Wongs Jewellers was founded in Liverpool in 1979. The business has stayed independent ever since, built around in-house craftsmanship, bespoke design and the kind of personal service chain retailers struggle to match. Founder Mr. Wong brought his Chinese heritage into the brand from the start, and it still shows up in the story the company tells and the pieces it sells. The workshop remains the heart of the operation. Across the North West of England, Wongs has become the name people think of for engagement rings and bridal jewellery.

For the Manchester store project, DG Display Showcase’s team worked with Wongs to understand the brand’s concept, history and spatial requirements before developing the display and interior solution. The design process considered brand heritage, customer circulation, product presentation and lighting atmosphere as connected elements of the retail experience, allowing display cases, counters and other fixtures to contribute to the wider visual identity of the store rather than function as separate furnishings.

The project included customized jewelry display showcases, premium counter displays, island displays, wall-mounted cabinets, an experience table and complementary retail fixtures, coordinated around Wongs’ individual design concept and material requirements rather than a standardized display package.

From Design Concept to International Delivery

The project also illustrates the practical demands of cross-border retail-space execution. Wongs Jewellers was introduced to DG Display Showcase through a customer referral and subsequently evaluated the company’s track record across the UK and other international markets — one of more than 200 customized projects DG Display Showcase completes globally each year from its Guangzhou manufacturing base. The two teams then worked through the design concept, materials and spatial details together before reaching agreement on the final solution.

For DG Display Showcase, the project required coordination across design, production and delivery while maintaining consistency between the approved concept and the finished fixtures. The company’s one-stop model is designed to keep these stages connected, extending beyond manufacturing to transportation and after-sales maintenance and repair — an approach intended to give overseas clients confidence when working with a manufacturing partner based in China.

“DG Display Showcase did more than understand our brand; they truly incorporated our brand philosophy into the space,” said Peter Wong, Managing Director of Wongs Jewellers. “Their professionalism and attention to detail helped give the store a distinctive character.”

The completed Manchester store became part of Wongs Jewellers’ wider recognition at the 2026 UK Jewellery Awards. In its own account of the ceremony, Wongs described its four shortlists and two wins as recognition of the creativity, customer experience and dedication of its wider team.

For DG Display Showcase, the project demonstrates how customized jewelry display manufacturing can be integrated with broader retail-space planning to help international jewellery brands express heritage, organize customer experiences and maintain consistency from design through delivery.

As luxury jewellery retailers place greater emphasis on the environment surrounding the product, DG Display Showcase continues to position its display expertise within a broader retail-space service model, combining design, engineering, manufacturing and project support for customized jewellery and luxury retail environments worldwide.

About DG Display Showcase

Founded in 1999 and headquartered in Guangzhou, China, DG Display Showcase develops customized display and retail-space solutions for jewellery, watches, perfume, museums and luxury retail environments. With more than 27 years of industry experience and more than 9,000 completed brand store projects worldwide, the company provides services spanning design, engineering, manufacturing, logistics, installation support and after-sales service. DG Display Showcase works with international clients on customized display systems and one-stop retail solutions developed around individual brand and project requirements.

Media Contact:

Official website: https://www.degreefurniture.com/
Company Name: DG Master of Display Showcase Co.,Ltd
Email: sales@degreefurniture.com
WhatsApp: +86 13922429233

LOS ANGELES, Aug. 17, 2026 /PRNewswire/ — XPPen, a global leader in digital art innovation, today unveiled the Artist Ultra 14, an Ultra Clear True Color Portable Drawing Display featuring a 2.8K OLED display, studio-grade color performance, the advanced X-Touch solution, and an ultra-slim design. Marking XPPen’s 21st anniversary, the Artist Ultra 14 combines flagship-level performance with exceptional portability, empowering creators to bring professional creativity wherever inspiration strikes.

“Creative workflows are becoming increasingly flexible, and creators today need tools that can adapt to the way they work,” said Brian Huang, Marketing Director at XPPen. “The Artist Ultra 14 is designed for professional creators seeking greater mobility without compromising visual quality or creative performance. It gives artists the freedom to create across different environments, expanding the possibilities of professional digital art.”

Professional-Grade Performance for Creative Excellence

The Artist Ultra 14 features a 2.8K OLED display with a True RGB Stripe pixel arrangement, native 10-bit color depth, and 99% Adobe RGB, 99% sRGB, and 99% Display P3 color gamut coverage, delivering exceptional clarity and true-to-life colors. With Delta E < 1 color accuracy and Calman Verified certification, it ensures reliable color precision for illustrations, animations, and other professional creative workflows.

With a 90Hz refresh rate and ultra-fast OLED response time, the Artist Ultra 14 minimizes motion blur and pen latency for smoother pen strokes and fluid playback. A 100,000:1 contrast ratio further enriches visual depth with finer shadow detail and more lifelike images. Its AG nano-etched glass surface helps reduce glare in bright environments, while the hybrid dimming solution minimizes flicker, helping to reduce eye strain during extended creative sessions.

Beyond visual performance, the Artist Ultra 14 provides a natural and intuitive drawing experience with two X3 Pro series styli, each supporting 16K pressure levels and 60° tilt recognition for precise and responsive strokes. XPPen’s X-Touch solution further streamlines interaction with intuitive multi-finger gestures, customizable touch zones, and a floating shortcut menu, allowing creators to navigate and control their canvas with greater efficiency. The new virtual tablet mode lets creators use the stylus to control up to 10 screens with smooth cross-screen operation, making it easy to drag files and move windows seamlessly.

Built around the way creators work, the Artist Ultra 14 features two side buttons preset for the floating menu and virtual tablet interface, while remaining customizable to suit individual workflows. Together with the included ACK05 Shortcut Remote, foldable stand, and pen case, it provides a complete and efficient creative setup.

Ultra-Slim Design for Creative Mobility

At just 6mm thin and weighing only 720g, the Artist Ultra 14 is engineered for effortless portability for creators who work across multiple locations. Its 16:10 display provides more vertical workspace than traditional 16:9 screens, offering additional room for toolbars, timelines, and creative workflows. Combined with a floating etched glass design and an ultra-narrow 14.5mm bezel, the display maximizes every inch of space to deliver an immersive, near-borderless canvas that keeps creators focused on their work.

The slightly curved edges provide a more comfortable wrist-resting position during extended creative sessions, while the aluminum alloy back panel enhances heat dissipation and structural durability. For flexible creative setups, a single full-featured USB-C connection supports power, video, and data transmission through one cable, enabling a clean, clutter-free workspace and quick setup whether at home, in the studio, or on the go.

Price & Availability

The Artist Ultra 14 is available starting August 17, 2026, at a retail price of $699. Pricing and availability may vary by region. For more information, please visit: https://www.xp-pen.com/product/artist-ultra-14.html.

CHENGDU, China, Aug. 17, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company“, Stock Code: 6990.HK) announces its unaudited consolidated results for the period ended 30 June 2026 (the “Reporting Period“).

Key information is as follows:

• Revenue amounted to approximately RMB 978 million, with sales of pharmaceutical products reaching RMB 657 million, up by 112% compared to the same period last year, driven by two factors: expert recognition of high quality clinical data and shift in treatment paradigms, and comprehensive enhancement of drug accessibility.
• The Company has established a comprehensive operational system in China encompassing R&D, manufacturing, quality management, and commercialization, with integrated drug development capabilities. The Company is also pursuing global expansion through international collaborations, leveraging external partnerships to accumulate global clinical development and commercialization experience, while exploring diversified pathways to progressively achieve independent overseas market entry.
• Focusing on ADC and novel DC, the Company not only has two ADC products that have been approved for marketing, but has also built a product pipeline that is differentiated and complimentary to approved ADCs in indications, efficacy performance and safety profile. Through the free combination of conjugation drug components, as well as the pairing with a diverse range of targeting conjugates including antibodies, small molecules, and peptides that leverage TAA/IO/ anti-angiogenetic-based mechanisms, the Company has proactively positioned innovative DC assets, including single-payload DCs such as radioisotope-based/ immuno-agonist-based/degrader-based, and dual-payload DCs such as cytotoxin + cytotoxin or immuno-agonist or degrader combinations, among others.
• Doubling down on ADC + IO therapies, including the combination of ADCs with PD-(L)1 or PD-1/VEGF agents, as well as the development of drug candidates with synergetic MoAs within one ADC compound.
• Beyond oncology, the Company has also expanded into important therapeutic areas such as autoimmune and metabolic diseases, and is currently conducting multiple clinical studies for asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis.

Clinical development progresses efficiently, with a tiered expansion of the pipeline matrix

Focusing on high-incidence tumors such as lung cancer and breast cancer, the Company has built a well-layered clinical pipeline with significant synergistic potential, covering drug modalities including ADCs, immunotherapies, and small-molecule targeted therapies, while further expanding into major therapeutic areas such as autoimmune and metabolic diseases.

Approved ADC Products

Sac-TMT (TROP2 ADC, sacituzumab tirumotecan) (also known as SKB264/MK-2870) (佳泰莱^®)
The product has currently received marketing approval for four indications, namely 2L+ TNBC, 2L/3L EGFR-mutant NSCLC, and 2L+ HR+/HER2- BC. In addition, two new indication drug applications have been accepted for review, covering the combination with pembrolizumab for 1L PD-L1-positive NSCLC, and as a monotherapy for 1L TNBC.

Clinical progress in the reporting period:

• Marketing approval for 2L+ HR+/HER2- BC
• New indication drug applications accepted for 1L TNBC and 1L PD-L1-positive NSCLC
• The OptiTROP-Lung06 registrational trial in China for 1L PD-L1-negative non-squamous NSCLC met primary endpoint
• The global Phase 3 TroFuse-005 trial for 2L+ EC met primary endpoints
• Two global Phase 3 trials for OC & UC initiated in H1 2026
• Phase 2 study in combination with SKB118 for NSCLC initiated
• Granted BTD for 1L PD-L1-positive NSCLC from NMPA

Drawing on all the aforementioned key advances, sac‑TMT has clearly embodied four core development strategies: advancing from monotherapy to combo-therapy, shifting from later-line to earlier-line treatment settings, expanding indications, and conducting clinical research from China to the global.

Trastuzumab botidotin (HER2 ADC, also known as A166) (舒泰莱^®)
One indication has received marketing approval for the treatment of 2L+ HER2+ BC. Its Phase 2 clinical study in HER2+ BC patients previously treated with topoisomerase inhibitor ADCs is ongoing.

Other ADC and novel DC assets

The Company has also built a pipeline of innovative assets that are differentiated from and complementary to approved ADCs in indications, efficacy and safety profile, including SKB315 (CLDN18.2 ADC), SKB410 (Nectin-4 ADC), SKB571 (novel bsADC), SKB107 (RDC), SKB103 (TAA-IO bsADC), and SKB565 (novel dual-payload ADC), among others.

Non-DC Assets

Clinical progress in the reporting period:
SKB118/CR-001 (PD-1/VEGF bsAb): The IND application for the treatment of solid tumors has been approved by the NMPA, and a Phase 1/2 clinical trial is ongoing.
SKB378/WIN378 (TSLP mAb): A Phase 1 clinical trial in healthy subjects has been completed in China, and its IND application for the treatment of COPD has also been approved by the NMPA.
SKB575 (TSLP/undisclosed target bsAb): Phase 1 clinical trials for atopic dermatitis and asthma are ongoing in China.

Major Key Research Findings Presented at International Academic Conferences & Journals

• The Phase 3 trial evaluating sac-TMT plus pembrolizumab versus pembrolizumab monotherapy for first-line treatment of PD-L1-positive advanced NSCLC was delivered as an oral presentation at ASCO 2026 and concurrently published in The Lancet. Compared with single-agent immunotherapy, this combination regimen yielded a significant prolongation in PFS (HR = 0.35), with consistent PFS benefits observed across all predefined subgroups; an OS benefit trend was also observed (HR = 0.55).
• The final OS analysis results from the pivotal study of sac-TMT for 3L EGFR-mutant NSCLC were selected as a LBA at ELCC 2026 and presented as a mini oral presentation.
• Lunbotinib Fumarate Capsules (RET inhibitor, also known as A400/EP0031) (宁泰莱^®[1]): Key Phase 2 clinical results for advanced RET fusion-positive NSCLC were presented in an oral presentation at ASCO 2026.

Multiple products gain market traction, with robust commercial growth momentum

To date, the Company has received marketing authorization for sac-TMT (佳泰莱^®), tagitanlimab (科泰莱^®), Cetuximab N01 (达泰莱^®) and trastuzumab botidotin (舒泰莱^®), of which 3 products covering 5 indications have been included in the National Reimbursement Drug List (NRDL). The Company has also submitted an NDA for Lunbotinib Fumarate Capsules, and upon regulatory communication and marketing approval, commercialization is expected to commence in the first half of 2027. With this, the Company’s initial commercial product portfolio, comprising 5 products, has taken shape.

In the first half of 2026, the total revenue from sales of pharmaceutical products reaching RMB 657 million, up by 112% compared to the same period last year.

Major growth drivers:

Expert Recognition of High‑Quality Clinical Data and Shift in Treatment Paradigms:

• Data from a number of high‑quality clinical studies of international caliber have continued to be released, thereby continuously reinforcing the evidence-based clinical foundation of our products.
• Recognized through authoritative endorsement from clinical guideline experts, as reflected in guidelines (CSCO, etc.) and clinical expert consensus.
• 佳泰莱^® is recognized as the “standard of care in 2L and the preferred regimen in 3L” in the LC, and is also the preferred brand among TROP2 ADC in TNBC.
• Through ongoing medical education and academic exchange activities, clinicians have gained a deeper understanding of the products. Treatment paradigms have also evolved gradually.

Comprehensive Enhancement of Drug Accessibility

• Effective translation of the benefits of NRDL inclusion: 3 indications of 佳泰莱^® and 达泰莱^® have been included in the 2025 NRDL, which officially took effect on January 1, 2026. This marks 佳泰莱^® the only TROP2 ADC and the only domestic ADC in TNBC/NSCLC under the NRDL
• Broader hospital access channels: Covers 30 provinces, over 300 prefectures and over 2,000 hospitals; Broaden reimbursement channels, including formal access, temporary procurement and dual-channel reimbursement;
• Continuous expansion of the commercialization team: Established a team of 800+; nearly doubling YoY; Achieved extensive grassroots coverage of top-tier hospitals in high-potential districts

Sac-TMT (佳泰莱^®) achieved positive results in its first global Phase 3 trial, accelerating global collaboration progress

• Collaboration with Merck Sharp & Dohme (hereinafter referred to as the “MSD”) (默沙东): MSD has initiated 17 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other agents for several types of cancer, with indications covering breast cancer (BC), lung cancer (LC), gynecologic cancers, gastrointestinal (GI) cancers, and genitourinary (GU) cancers.
  In May 2026, MSD announced that the pivotal Phase 3 Trofuse-005 trial met its primary endpoints of OS and PFS in certain patients with advanced or recurrent EC. TroFuse-005 is the first global Phase 3 trial to demonstrate statistically significant improvement in both OS and PFS compared to chemotherapy for these patients, and sac-TMT is the first and only ADC to do so for patients with EC in this setting.
  Beyond sac‑TMT, the Company has also entered into collaborations with MSD on certain ADC assets, continuously exploring the optimal ADC pipeline portfolio.
• Collaboration with Ellipses Pharma: Lunbotinib Fumarate Capsules (A400/EP0031) have received FDA approval to proceed into Phase 2 clinical development. A total of 42 clinical trial sites has been established in the United States, UK, Europe, and the United Arab Emirates for Lunbotinib Fumarate Capsules.
• Collaboration with Windward Bio: Windward Bio is evaluating SKB378/WIN378 in the POLARIS Phase 2/3 global trial in patients with asthma and has dosed the first patients in the SIRIUS Phase 2 global study in patients with COPD.
• Collaboration with Crescent Biopharma: Entered into a licensing collaboration with Crescent Biopharma for SKB105/CR-003.

ESG capabilities continue to strengthen, delivering outstanding results in capital market performance.

In terms of ESG, in May 2026, the Company was included in the “China ESG Impact List” by Fortune and was awarded bronze medal for “Most Committed to ESG (China)” under “Asia’s Best Company” by FinanceAsia. In March 2026, the Company had received a rating of “AA” in the MSCI ESG Rating Assessment.

In terms of capital markets, the Company was approved by the Hong Kong Stock Exchange to officially remove the “B” marker from its stock code on April 14, 2026. In addition, the Company completed the placing of H Shares in July 2026, with net proceeds from the Placing amounting to approximately HK$2,723.4 million.

Prospect

Kelun-Biotech will continue to drive innovation and strengthen its operational capabilities, steadily advancing towards becoming a world-class biopharmaceutical company. Specifically, the Company will implement the following development strategies: advancing differentiated pipelines targeting indications with significant medical needs; optimizing payload-linker strategies and novel DC designs and structures, while expanding applications in non-oncology diseases; enhancing its end-to-end drug development and commercialization capabilities; expanding its global footprint through strategic partnerships and improve our capabilities for the development, registration and commercialization of our products in ex-China market; and optimizing its operational systems with the aim of becoming a leading global biopharmaceutical company.

－End－

About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 2 projects with 3 indications are in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.